Bionano Genomics Inc (BNGO) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Bionano Genomics Inc   (NASDAQ: BNGO)

Bionano Genomics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Bionano Genomics Inc in the second quarter 2026?
Bionano Genomics Inc recorded a cumulative net loss of $-32 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -78.78%.

Within the Laboratory Analytical Instruments industry 19 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2917 to 3329.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -30.34 % -22.26 % 25.58 % 1.91 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -32 -32 -26 -39 -74
Return On Equity (TTM) -78.78 % -71.38 % -56.22 % -86.36 % -167.22 %
BNGO's Total Ranking # 3329 # 2917 # 2913 # 3219 # 2948
Equity (TTM) in Millions 32 37 44 50 45
Seq. Equity Change -15.63 % -15.67 % -10.79 % 9.75 % -5.84 %
Seq. Net Income Change - - - - -

Back to BNGO Management Effectiveness >> BNGO's 5 Years Annual ROE >> Compare BNGO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 20
Sector # 506
Overall # 3329

Return On Equity Statistics
High Average Low
-20.89 %
-758.14 %
-15680.11 %
(Dec 31 2021)   (Dec 31 2019)



  News about Bionano Genomics Inc Return on Equity ROE

Amidst Financial Hurdles, Bionano Genomics Pioneers Optical Genome Mapping as an Innovative Solution for Genetic Diagnostics,

IntroductionBionano Genomics, Inc. (Nasdaq: BNGO) has made significant strides in the field of genetic diagnostics with its innovative Optical Genome Mapping (OGM) technology. Recent peer-reviewed publications highlight OGM s accuracy and cost-effectiveness in identifying and sizing large repeat expansions associated with numerous genetic disorders. However, alongside these scientific achievements, the company faces considerable financial challenges, including a substantial cumulative net loss. This article outlines the findings from recent studies and provides a comprehensive overview of Bionano s positioning within the laboratory analytical instruments sector.Optical Genome Mapping: Insights from Recent Research1. Publication Overview - A groundbreaking study published in Genome Research on April 23, 2025, led by Alexander Hoischen at Radboud University Medical Center, evaluated OGM in the context of large repeat expansion disorders. - The research examined 85 subjects with known pathogenic expansions in three genes: - DMPK : Linked to myotonic dystrophy type 1 (DM), the condition characterized by muscle weakness and wasting. - CNBP : Associated with myotonic dystrophy type 2. - RFC1 : Connected to cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS), a disorder marked by coordination loss and sensory nerve damage. - Findings indicate OGM can serve as an accurate, single-workflow solution for these genetic diagnostic challenges.



BNGO Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 44 35 96 249 337
Y / Y Equity Change 25.58 % -63.21 % -61.44 % -26.02 % 860.94 %
Net Income in Millions -26 -112 -232 -133 -72
Y / Y Net Income Change - - - - -
Return On Equity -59.42 % -316.66 % -241.78 % -53.17 % -21.49 %

Back to BNGO Management Effectiveness >> BNGO's 5 Years Annual ROE >> Compare BNGO ROE to its Competitors




More Return On Equity Ratios
Laboratory Analytical Instruments Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BNGO's' Return on Equity at Yahoo Finance
BNGO's Roe Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BNGO's Competitors
Subscribers only: Roe for Bionano Genomics Inc 's Suppliers
Subscribers only: Return On Equity for BNGO's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-08T16:48:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.